Stock listing
NASDAQ:GBIO Generation Bio Co Stock
Follow Generation Bio Co into a list and get an email when it puts out news.
Last close · NASDAQ:GBIO
$5.34 USD
Close on Feb 6, 2026 · No longer trades
- Lowest – highest close
- $4.04 – $6.71 USDSince Jul 22, 2025 · lowest Aug 11, 2025 · highest Oct 15, 2025
Delisted NASDAQ:GBIO no longer trades. Its last trading date is unknown. Company history and updates stay available on this page.
- Ticker
- NASDAQ:GBIO
- Asset type
- Stock
- Exchange
- NASDAQ
- Currency
- USD
Generation Bio Co on 6ix
- Decks
- 4 decks · latest Sep 26, 2024
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| BPI East 2024 | Conference | 21 slides | Sep 26, 2024 |
| ESGCT 30th Annual Congress (October 2023) | Conference | 23 slides | Oct 26, 2023 |
| Technical Presentation (October 2023) | Technical | 4 slides | Oct 26, 2023 |
| OTS Webinar October 2023 | Conference | 36 slides | Oct 12, 2023 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Charles A Rowland Jr Other companies: Viking Therapeutics, Inc. (Director · Since at least Jul 1, 2017); Orchard Therapeutics PLC (Director · Jan 1, 2020 – Jan 24, 2024 · Past); Nabriva Therapeutics AG (Director · Dec 30, 2016 – Aug 3, 2022 · Past); Blueprint Medicines Corp (Director · Apr 30, 2015 – Jun 2, 2021 · Past); Vitae Pharmaceuticals Inc (Director · Sep 24, 2014 – Oct 25, 2016 · Past); BIND Therapeutics Inc (Director · May 28, 2014 – Jun 21, 2016 · Past); Idenix Pharmaceuticals Inc (Director · Jun 6, 2013 – Aug 5, 2014 · Past); Viropharma Inc (VP, Chief Financial Officer · Oct 20, 2008 – Jan 24, 2014 · Past) | Director · Since at least Jun 11, 2020 |
| Stephen J DiPalma Other companies: Inozyme Pharma Inc (Interim CFO · May 17, 2021 – May 17, 2021 · Past); Solid Biosciences Inc. (Interim CFO · Jan 29, 2021 – Jan 29, 2021 · Past); Chemomab Therapeutics Ltd. (Chief Financial Officer · May 1, 2020 – May 1, 2020 · Past); Spero Therapeutics, Inc. (See Remarks · Nov 8, 2019 – Jul 15, 2023 · Past); Interleukin Genetics Inc (Interim CFO · Jul 29, 2016 – Jul 29, 2016 · Past) | See Remarks · Jun 11, 2020 – Jun 11, 2020 · Past |
| Jason Rhodes Other companies: Dyne Therapeutics, Inc. (Chairman · Since at least Sep 16, 2020); Disc Medicine, Inc. (Director · Feb 5, 2021 – Oct 4, 2021 · Past); Replimune Group, Inc. (Director · Jul 19, 2018 – Apr 1, 2022 · Past); Epizyme Inc (President, CFO and Treasurer · May 30, 2013 – Sep 22, 2014 · Past) | Director · Since at least Jun 11, 2020 |
| Catherine Stehman-Breen Other companies: Tenaya Therapeutics, Inc. (Board Member · Since at least Jul 29, 2021); Dyne Therapeutics, Inc. (Board Member · Since at least Jul 31, 2020); Sarepta Therapeutics, Inc. (SVP, Chief Medical Officer · Apr 3, 2017 – Apr 3, 2017 · Past) | Director · Since at least Jun 11, 2020 |
| Jeffrey M Jonas Other companies: COMPASS Pathways Plc (Director · Since at least Oct 29, 2025); Karuna Therapeutics Inc (Director · Jun 27, 2019 – Mar 15, 2024 · Past); Sage Therapeutics Inc (Director · May 23, 2019 – Jun 10, 2024 · Past) | Director · Since at least Jun 11, 2020 |
| Ron Cooper Other companies: enGene Therapeutics Inc. (Chief Executive Officer · Since at least Jul 22, 2024); C4 Therapeutics, Inc. (Director · Since at least Jun 7, 2024); Albireo Pharma Inc (President and CEO, Director · Nov 3, 2016 – Mar 2, 2023 · Past) | Director · Since at least Mar 1, 2021 |
| Donald William Nicholson Other companies: Disc Medicine, Inc. (Director · Since at least Dec 29, 2022); Kymera Therapeutics, Inc. (Director · Jun 16, 2021 – Jun 15, 2022 · Past) | Director · Since at least Jan 11, 2021 |
| Geoff McDonough Other companies: Third Harmonic Bio Inc. (Director · Mar 27, 2024 – Mar 27, 2024 · Past); Surface Oncology Inc (Director · Jun 5, 2019 – Jun 8, 2021 · Past) | Director · Since at least Jun 11, 2020 |
| Gustav Christensen Other companies: Morphic Holding Inc (Director · Jun 26, 2019 – Aug 16, 2024 · Past); Dyax Corp (CEO and President, Director · Apr 26, 2007 – Jan 14, 2016 · Past) | Director · Since at least Jun 11, 2020 |
| Douglas Kerr Other companies: Dyne Therapeutics, Inc. (Head of R&D and CMO · Since at least Sep 3, 2024) | CHIEF MEDICAL OFFICER · Jun 11, 2020 – Jan 29, 2024 · Past |
All 19 people
| Person | Seat |
|---|---|
| Matthew Norkunas Other companies: Obsidian Therapeutics, Inc. (Director · Since at least Aug 3, 2026) | CHIEF FINANCIAL OFFICER · Jan 22, 2021 – Jan 10, 2025 · Past |
| Yalonda Howze Other companies: Codiak BioSciences Inc (See Remarks · Jul 2, 2020 – Mar 30, 2023 · Past) | INTERIM CEO AND PRESIDENT · Since at least Apr 5, 2023 |
| Anthony G Quinn | Director · Since at least Jun 4, 2025 |
| Antoinette Paone | CHIEF OPERATING OFFICER · Since at least Feb 10, 2022 |
| Kevin John Conway | CHIEF FINANCIAL OFFICER · Since at least Jan 10, 2025 |
| Mark D Angelino | CHIEF OPERATING OFFICER · Jun 11, 2020 – Feb 5, 2021 · Past |
| Matthew Stanton | CHIEF SCIENTIFIC OFFICER · Jun 11, 2020 – Jan 10, 2025 · Past |
| Phillip Samayoa | CHIEF SCIENTIFIC OFFICER · Since at least Sep 16, 2022 |
| Tracy Zimmermann | CHIEF DEVELOPMENT OFFICER · Nov 9, 2020 – Jan 29, 2024 · Past |
Log in to ask 6ix AI your own questions about Generation Bio Co.